权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

EXODOTS for diagnostic evaluation and monitoring of Alzheimer's disease

EXODOTS 用于阿尔茨海默病的诊断评估和监测

基本信息

批准号：
10600890
负责人：
Yuchao Chen
金额：
$ 29.17万
依托单位：
WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10600890
关键词：
Alzheimer disease detection Alzheimer disease screening Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease diagnostic Alzheimer&apos s disease model Alzheimer&apos s disease patient Alzheimer’s disease biomarker Biological Assay Biological Markers Biomedical Technology Blood Blood - brain barrier anatomy Blood Circulation Blood Proteins Blood Tests Brain Brain Injuries Cerebrospinal Fluid Clinical Collection Cross Reactions Data Data Analyses Detection Development Diagnostic Diagnostic Procedure Disease Disease Progression Early Diagnosis Evaluation Goals Hour Immunofluorescence Immunologic Measurement Measures Mediator of activation protein Membrane Proteins Methods Monitor Neurodegenerative Disorders Neurons Neuropsychological Tests Noise Non-Invasive Cancer Detection Outcome Outpatients Pathogenesis Peripheral Phase Plasma Plasma Proteins Procedures Proteins Psyche structure Reporting Sampling Sensitivity and Specificity Severity of illness Signal Transduction Small Business Innovation Research Grant Source Specificity Speed Statistical Data Interpretation Technology Testing Update base biomarker panel circulating biomarkers clinical diagnosis cohort cost cost effective design detection assay detection limit detection sensitivity diagnosis evaluation diagnostic tool disease diagnosis extracellular vesicles improved innovation liquid biopsy minimally invasive multiplex detection neuroimaging noninvasive diagnosis novel primary care setting screening tau Proteins technological innovation

项目摘要

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder. Despite the severity of the disease, early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Development of an accurate and cost-effective technology for non-invasive screening and monitoring of AD before irreversible brain damage or mental decline is critical. WellSIM proposes to develop and validate a highly sensitive immunofluorescence assay, termed EXODOTS, for detection and quantification of AD core biomarkers from circulating extracellular vesicles (EV) with high accuracy, high speed, and low cost. This blood-based assay will facilitate minimally invasive assessment of AD patients in primary care settings and continuous monitoring of disease progression.

项目总结/摘要阿尔茨海默病（Alzheimer's disease，AD）是最常见的神经退行性疾病。尽管疾病很严重，由于神经心理学测试的低准确性或高成本，AD的早期诊断仍然具有挑战性，神经成像开发一种准确和具有成本效益的非侵入性筛查技术，在不可逆的脑损伤或智力衰退之前监测AD是至关重要的。WellSIM建议开发和验证用于检测和定量AD的高灵敏度免疫荧光测定法（称为EXODOTS）以高准确度、高速度和低成本从循环细胞外囊泡（EV）中提取核心生物标志物。这基于血液的检测将有助于在初级保健环境中对AD患者进行微创评估，持续监测疾病进展。